The Pharma Data

JUNE 15, 2025

This update comes after two cases of fatal acute liver failure (ALF) were reported in non-ambulatory DMD patients who received Elevidys, a phenomenon that underscores the ongoing complexities and safety signals related to adeno-associated virus (AAV)-mediated gene therapy.

Regulations 40

Regulations Clinical Trials Trials Treatment 40

Codon

JUNE 5, 2025

If the same virus invades the cell a second time, the gRNA’s spacer sequence will bind to the matching viral DNA sequence, then be cut by the Cas protein. Dozens more clinical trials, based upon similar gene-editing technologies, are now underway.

DNA 83

DNA RNA Clinical Trials Engineering 83

New Drug Approvals

JUNE 28, 2025

By binding to the active site of the protease, the drug prevents this cleavage process, effectively halting viral assembly and impeding the virus’s ability to produce future virions. [1] The drug appeared to shorten the recovery time of 11 COVID-19 symptoms in olgotrelvir-treated patients by 2.4 67 (11): e0084023. doi : 10.1128/aac.00840-23.

Clinical Trials 57

Clinical Trials Production Treatment Trials 57

Drug Target Review

MAY 26, 2025

“A big part of my role involves interacting with customers, learning from them on their challenges and providing solutions to expedite their path to clinical trials or commercialisation of their drug,” Galbraith explains. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.

Drug Development 52

Drug Development Drugs Therapies Pharmaceuticals 52

Codon

NOVEMBER 1, 2024

Although Amodei does acknowledge some real-world issues limiting scientific progress — such as the slow growth of organisms and tedious clinical trials — he mostly passes over the more general tools that will be required to accelerate research in the near term. This essay focuses on how we might do both, specifically for the cell.

DNA 133

DNA RNA Molecular Biology Laboratories 133

BioPharma Drive: Drug Pricing

JULY 10, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. You can unsubscribe at anytime. TechTarget, Inc.s

Vaccine 226

Vaccine FDA Therapies Licensing 226

BioPharma Drive: Drug Pricing

JULY 10, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales.

Drugs 221

Drugs Licensing Licensing Therapies 221

The Pharma Data

JUNE 19, 2025

Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols , a globally recognized healthcare company and a leader in the production of plasma-derived therapies, has marked a significant advancement in the treatment of acquired fibrinogen deficiency (AFD).

Therapies 40

Therapies Trials Clinical Trials Medical Schools 40

The Pharma Data

JUNE 11, 2025

With this approval, MAVYRET becomes the first and only DAA treatment approved to treat both acute and chronic hepatitis C virus (HCV) infections in patients as young as three years old, with or without compensated cirrhosis, using an eight-week regimen. Safety outcomes from the trial further bolster the confidence in MAVYRET’s use.

FDA Approval 40

FDA Approval FDA Virus Therapies 40

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from News roundup Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules Biocryst is offloading part of its business to an Italian drugmaker for $250 million upfront.

Vaccine 130

Vaccine FDA Therapies Licensing 130

Science Daily: Pharmacology News

MAY 15, 2025

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional approaches haven't worked -- largely because HIV mutates rapidly and hides key parts of itself from the immune system.

Vaccine 257

Vaccine Trials Immune Response Clinical Trials 257

Drugs.com

AUGUST 1, 2024

1, 2024 -- A next-generation nasal vaccine for COVID-19 appears to do what injectable vaccines can’t -- actually stop the spread of the virus from person to person.Hamsters that received the nasal vaccine didn’t pass the virus on to. THURSDAY, Aug.

Vaccine 276

Vaccine Virus Trials 276

BioPharma Drive: Drug Pricing

SEPTEMBER 12, 2024

Spun out of research at Nationwide Children’s Hospital, Vironexis claims it will be the first company to start a study testing a cancer drug delivered via the adeno-associated viruses commonly used in genetic medicines.

Therapies 278

Therapies Virus Trials Hospitals 278

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 246

Vaccine Trials Virus Research 246

New Drug Approvals

JULY 18, 2025

9] Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)). It was approved in China in 2021 as a first-in-class treatment for human immunodeficiency virus (HIV). 6] [7] Azvudine was first discovered in 2007. [8] Swallow, S.;

RNA 62

RNA Clinical Trials Virus Trials 62

Science Daily: Pharmacology News

AUGUST 17, 2023

A single injection of a novel CRISPR gene-editing treatment safely and efficiently removes SIV -- a virus related to the AIDS-causing agent HIV -- from the genomes of non-human primates, scientists now report.

Virus 187

Virus Treatment Clinical Trials FDA 187

BioPharma Drive: Drug Pricing

SEPTEMBER 19, 2024

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.

Virus 257

Virus Trials Drugs 257

Science Daily: Pharmacology News

APRIL 23, 2025

A bacteria killing coating created by scientists has been used in trials of a new paint that can be applied to a range of surfaces to effectively kill bacteria and viruses, including difficult to kill species such as MRSA, flu and COVID-19.

Virus 201

Virus Trials 201

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Trials Treatment Virus 105

Drugs.com

OCTOBER 4, 2023

Now, a new trial finds antiviral medications, when given soon after a child is diagnosed. WEDNESDAY, Oct. 4, 2023 -- Recent research has suggested that viruses could play a role in the loss of pancreatic beta cells, which triggers type 1 diabetes.

Virus 124

Virus Trials Research 124

The Pharma Data

SEPTEMBER 14, 2020

. AstraZeneca has confirmed that clinical trials assessing its Oxford University partnered coronavirus vaccine AZD1222 have resumed in the UK, following a green light by the Medicines Health Regulatory Authority (MHRA). Source link. Source link.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Discovery Today

AUGUST 18, 2022

The large European interventional clinical study is investigating protection against Respiratory syncytial virus (RSV) in infants. HARMONIE is an open label trial that will evaluate the use of nirsevimab, a passive immunisation, in a broad population.

Virus 100

Virus Trials Research 100

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine. Molecular insights of HIV Reverse transcriptase and it's inhibitors.

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Pharma Data

AUGUST 13, 2020

With most vaccine trials ending in failure, the government is effectively hedging its bets, hoping that at least one of the vaccines it has purchased proves safe and effective. Inactivated whole virus vaccines: 60 million doses Valneva. In theory, there should be enough for everyone in the UK to get five doses.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

SCIENMAG: Medicine & Health

NOVEMBER 6, 2023

The fight against dengue fever has a new weapon: a mosquito infected with the bacteria Wolbachia, which prevents the spread of the virus. These mosquitoes have now been deployed in several trials demonstrating their potential in preventing disease transmission.

Virus 89

Virus Trials Disease 89

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada. Conor Kavanagh. Source link.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

AUGUST 20, 2020

NHS staff are taking part in a trial to see if dogs can sniff out Covid-19 – even in people who are asymptomatic. If the trial is successful, the dogs could be used at UK airports to screen people arriving from abroad. If the trial is successful, the dogs could be used at UK airports to screen people arriving from abroad.

Trials 52

Trials Nurses Hospitals Virus 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The trial on 10,000 people will now see if the vaccine can prevent people getting ill.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

AUGUST 28, 2020

Celltrion Group has announced that the Korean Ministry of Food and Drug Safety has approved the company’s Investigational New Drug application for a Phase 1 trial for their coronavirus antiviral antibody treatment candidate.

Trials 52

Trials Treatment Clinical Trials Pharmacokinetics 52

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . These antibodies were higher than those seen in people who had recovered from the virus. Each patient was given two 100 microgram doses of the vaccine 28 days apart.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Although the first vaccines to receive Emergency Use Authorization by the U.S. So the team made polymersomes that were similar in size to SARS-CoV-2 and decorated them with many RBDs.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52